poisar

Stocks · News reference

Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer

Aug 17, 2026, 11:03 AMBenzinga Newsdesk

The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa ResultsRamat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF),

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CANF
Source
benzinga
Observed
Aug 17, 2026, 11:03 AM
Checked
Aug 17, 2026, 11:03 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jul 20, 2026, 11:00 AMCan-Fite Biopharma Ltd.

    Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

    Can-Fite BioPharma announced that its Phase 2a study results for Namodenoson in advanced pancreatic cancer patients have been accepted for poster presentation at ESMO Congress 2026. The study demonstrated durable disease stabilization and encouraging survival outcomes in third-line pancreatic cancer patients, with one patient remaining alive over 18 months after second-line treatment. The company plans to advance to a Phase 2b study combining Namodenoson with chemotherapy.

    Read original at globenewswire-inc
    CANF